Omega-3 Fatty Acids and Mortality Outcome in Patients With and Without Type 2 Diabetes After Myocardial Infarction: A Retrospective, Matched-Cohort Study

Clinical Therapeutics

Volumn 35, Issue 1, 2013, Pages 40-51

  Poole, Chris D ^a   Halcox, Julian P ^a   Jenkins Jones, Sara ^b   Carr, Emma S M ^c   Schifflers, Mathias G ^c   Ray, Kausik K ^d   Currie, Craig J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Global Epidemiology   (United Kingdom)

^c ABBOTT LABORATORIES   (United States)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; EARLY INTERVENTION; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIMARY MEDICAL CARE; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; RISK MANAGEMENT; SECONDARY PREVENTION; SMOKING; SOCIAL STATUS; SYSTOLIC BLOOD PRESSURE;

AGED; CARDIOVASCULAR AGENTS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FATTY ACIDS, OMEGA-6; FEMALE; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRIMARY HEALTH CARE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872416659     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.11.008     Document Type: Article

References (21)

1. Saravanan P. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010, 376:540-550.
2. Filion K.B., El Khoury F., Bielinski M., et al. Omega-3 fatty acids in high risk cardiovascular patients: meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2010, 10:24.
3. Yokoyama M., Origasa H. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J 2003, 146:613-620.
4. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447-455. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico).
5. Tavazzi L., Maggioni A.P., Marchioli A.P., et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230. Gissi-HF Investigators.
6. Marik P.E., Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009, 32:365-372.
7. Chen Q., Cheng L.Q., Xiao T.H., et al. Effects of omega-3 fatty acid for sudden cardiac death prevention in patients with cardiovascular disease: a contemporary meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther 2011, 25:259-265.
8. Kwak S.M., Myung S.K., Lee Y.J., et al. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease. Arch Intern Med 2012, 172:686-694.
9. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012, 367:309-318. The ORIGIN Trial Investigators.
10. Electronic Medicines Compendium (eMC). Omacor: summary of product characteristics Accessed October 11, 2012. http://www.medicines.org.uk/emc/medicine/10312/spc/omacor.
11. Herrett E., Thomas S.L., Schoonen W.M., et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010, 69:4-14.
12. MI: secondary prevention (clinical guideline CG48) May 2007, National Institute for Health and Clinical Excellence, Accessed October 11, 2012. http://www.nice.org.uk/nicemedia/pdf/CG48NICEGuidance.pdf.
13. Clayton D., Hills M. Time changing explanatory variables. Statistical Models in Epidemiology 1993, 3070-3318. Oxford University Press, Oxford, UK.
14. Winkleby M.A., Cubbin C. Influence of individual and neighbourhood socioeconomic status on mortality among black, Mexican-American, and white women and men in the United States. J Epidemiol Community Health 2003, 57:444-452.
15. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003, 24:1601-1610. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.
16. Van de Werf F., Ardissino D., Betriu A., et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003, 24:28-66. Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.
17. Smith S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006, 113:2363-2372. AHA/ACC, National Heart, Lung, and Blood InstituteNational Heart, Lung, and Blood Institute.
18. Nurse coordinated multidisciplinary, family-based cardiovascular disease prevention program (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008, 371:1999-2012. Euroaction Study Group.
19. Mozaffarian D., Wu J.H. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011, 58:2047-2067.
20. Rauch B., Schiele R., Schneider S., et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122:2152-2159. OMEGA Study Group.
21. Rizos E.C., Ntzani E.E., Bika E., et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012, 308:1024-1033.